Online citations, reference lists, and bibliographies.
← Back to Search

Preliminary Results From A Phase 1/2 Study Of INCB024360 Combined With Ipilimumab (ipi) In Patients (pts) With Melanoma.

Geoffrey T. Gibney, O. Hamid, Tara C. Gangadhar, J. Lutzky, A. Olszanski, T. Gajewski, Bartosz Chmielowski, P. Boasberg, Y. Zhao, R. Newton, P. Scherle, J. Bowman, J. Maleski, L. Leopold, J. Weber
Published 2014 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
3010 Background: Indoleamine 2,3-dioxygenase 1 (IDO1) is a tryptophan-catabolizing enzyme that is overexpressed in cancers and induces immune tolerance by suppressing T-cell responses. INCB024360, ...



This paper is referenced by
10.1172/JCI124077
IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma
A. Blair (2019)
10.1136/esmoopen-2016-000122
The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches
P. Economopoulou (2016)
10.20517/CDR.2018.015
Mechanism of resistance to immune checkpoint inhibitors
M. Pandey (2019)
10.1038/nrd4591
Combination cancer immunotherapy and new immunomodulatory targets
K. Mahoney (2015)
10.1007/978-3-319-11870-3_30
Clinical Trials Targeting the Kynurenine Pathway
Melanie Sheen (2015)
10.1053/j.seminoncol.2015.05.011
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.
T. Gajewski (2015)
10.1007/s13555-019-0292-3
Beyond PD-1 Immunotherapy in Malignant Melanoma
Dominika Kwiatkowska (2019)
The prOgnOsTic significance Of indOleamine-2,3- diOxygenase and The recepTOrs fOr TransfOrming grOwTh facTOr β and inTerferOn γ in meTasTaTic lymph nOdes in malignanT melanOma
M. Skłodowska-Curie (2015)
10.1016/j.ejca.2017.01.001
Second- and third-generation drugs for immuno-oncology treatment-The more the better?
W. Dempke (2017)
10.1007/s11523-017-0547-9
Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences
D. Davar (2017)
10.1007/s00281-018-0702-0
Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond
A. J. Muller (2018)
10.1371/journal.pone.0217276
Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice
T. Affolter (2019)
10.2217/imt.15.123
Immune checkpoint therapy for non-small-cell lung cancer: an update.
B. Xia (2016)
10.1007/978-3-319-63757-0_8
Immune Checkpoint Combinations with Inflammatory Pathway Modulators
N. DeVito (2018)
10.1080/2162402X.2015.1008814
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
A. Buqué (2015)
10.3389/fimmu.2014.00438
Early Carcinogenesis Involves the Establishment of Immune Privilege via Intrinsic and Extrinsic Regulation of Indoleamine 2,3-dioxygenase-1: Translational Implications in Cancer Immunotherapy
A. Holtzhausen (2014)
10.1097/PPO.0000000000000299
Clinical Development of PD-1 in Advanced Melanoma
R. Munhoz (2018)
10.1200/JCO.2014.59.4358
Immune Checkpoint Blockade in Cancer Therapy.
M. Postow (2015)
10.1158/1078-0432.CCR-16-3064
From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely
D. Day (2017)
10.5114/PJP.2015.57249
The prognostic significance of indoleamine-2,3-dioxygenase and the receptors for transforming growth factor β and interferon γ in metastatic lymph nodes in malignant melanoma.
M. Pelak (2015)
10.1002/bmc.3794
Determination of epacadostat, a novel IDO1 inhibitor in mouse plasma by LC-MS/MS and its application to a pharmacokinetic study in mice.
Vinay Kumar Dhiman (2017)
10.1080/2162402X.2016.1149674
Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy
A. Buqué (2016)
10.4161/21624011.2014.957994
Trial watch: IDO inhibitors in cancer therapy
E. Vacchelli (2014)
Utilisation d'un virus oncolytique pour traiter le cancer
Robert Coffin (2017)
10.1002/anie.201503323
Synthesis and Intracellular Redox Cycling of Natural Quinones and Their Analogues and Identification of Indoleamine-2,3-dioxygenase (IDO) as Potential Target for Anticancer Activity.
Christopher Blunt (2015)
10.1016/j.ygyno.2017.07.005
A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer.
R. Kristeleit (2017)
10.4155/fmc.15.165
The Janus-faced nature of IDO1 in infectious diseases: challenges and therapeutic opportunities.
F. Greco (2016)
10.1016/j.ejca.2017.01.011
The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy.
L. Brochez (2017)
10.1080/1744666X.2016.1176529
Harnessing the immune system for the treatment of melanoma: current status and future prospects
Andrea Guennoun (2016)
10.1007/978-4-431-55031-0_18
Anti-CTLA-4 Ab
T. Tokudome (2016)
10.1186/s40425-015-0094-9
Targeting the indoleamine 2,3-dioxygenase pathway in cancer
Y. Moon (2015)
10.1016/j.bbcan.2018.12.002
Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment.
Manni Wang (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar